Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46 , a Decrease of 22.2 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of

NORTH CHICAGO, Ill. , April 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT .

NORTH CHICAGO, Ill. , March. 8, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2023 . Robert A. Michael , vice chairman and president, Scott Reents , executive vice president, chief financial officer, Jeffrey R.

NORTH CHICAGO, Ill. , Feb. 28, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 . Robert A. Michael , vice chairman and president, Scott Reents , executive vice president, chief financial officer, Jeffrey R.

Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77 , an Increase of 16.4 Percent; These Results Include an Unfavorable Impact of $0.39 Per Share related to 2022 Acquired IPR&D and Milestones Expense 1 Delivers Full-Year Net Revenues of

NORTH CHICAGO, Ill. , Jan. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT .

NORTH CHICAGO, Ill. , Jan. 3, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 . Richard A. Gonzalez , chairman and chief executive officer, will present at 5:00 p.m. CT .

Reports Third-Quarter Diluted EPS of $2.21 on a GAAP Basis, an Increase of 24.2 Percent; Adjusted Diluted EPS of $3.66 , an Increase of 29.3 Percent; These Results Include an Unfavorable Impact of $0.02 Per Share related to Acquired IPR&D and Milestones Expense 1 Delivers Third-Quarter Net Revenues

NORTH CHICAGO, Ill. , Sept. 7, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 . Rob Michael , vice chairman and president, Jeff Stewart , executive vice president, commercial operations, and

Reports Second-Quarter Diluted EPS of $0.51 on a GAAP Basis, an Increase of 21.4 Percent; Adjusted Diluted EPS of $3.37 , an Increase of 11.2 Percent; These Results Include an Unfavorable Impact of $0.14 Per Share related to Acquired IPR&D and Milestones Expense 1   Delivers Second-Quarter Net